The effect of adding pyridostigmine to second generation antipsychotic drugs on schizophrenia symptoms: A double blind randomised placebo controlled clinical trial
Phase 3
- Conditions
- Schizophrenia.The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although
- Registration Number
- IRCT2015041521779N1
- Lead Sponsor
- Vice Chancellor for Research of Jondi Shapour University Of Medical Sciences of Ahvaz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
The main inclusion criteria is having schizophrenia disorder.inclusion criteria: The average age between 20 to 40 years and knowing persian language and having consent of participation in this research and having no brain organic disease and using no any anti depressants such as tricyclics drugs and donepezi drug.
Exclusion criteria :demensia and severe organic disease and very old age and young age and other neurologic diseases that patients must use anticholinesterase drugs and use of tricyclic antidepressants and donepezil drug.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Schizophrenic Disorder Symptom. Timepoint: In First And End Of 4 Weeks Of Research. Method of measurement: By Using Panss And Bprs Scales.
- Secondary Outcome Measures
Name Time Method Comparsion between complications of adding pyridostigmine with 2 generation antipsycotic drugs versus complications of antipsychotics alone. Timepoint: Along of research. Method of measurement: With recurrent visit of patients.